Japan 2012 approvals rise as regulatory reforms flow through
This article was originally published in SRA
A total of 44 new molecular and new biologic therapeutic entities (including new vaccines) were approved in Japan in calendar 2012, marking a substantial one-third increase over the33 in the previous year, according to Scrip Intelligence, a sister publication of Scrip Regulatory Affairs.
You may also be interested in...
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of PFS targets in the pancreatic setting.
Corporate consolidation and specialization were major threads running through the 2010s in Japan. Reimbursement pricing issues continued to dominate the policy sphere while new forms of therapy benefited from positive regulatory reforms.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.